---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-084319"
form_type: "8-K"
ticker: "BDSX"
cik: "0001439725"
company_name: "BIODESIX INC"
filed_at: "2025-04-17T23:59:59+00:00"
generated_at: "2026-05-23T11:45:14.103620+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# Two Biodesix directors resign effective May 20, 2025; Schuler named director emeritus

## Summary
- Charles Watts, M.D. resigns from Board and Compensation Committee effective at 2025 Annual Meeting (May 20, 2025).
- Jack Schuler resigns from Board and Nominating & Corporate Governance Committee, transitions to director emeritus (non-voting advisory role).
- Both resignations not due to any disagreement with Company's operations, policies, or practices.
- Dr. Watts served since July 2019; Mr. Schuler served since June 2008.

## SEC filing metadata
- accession: 0001193125-25-084319
- form_type: 8-K
- ticker: BDSX
- cik: 0001439725
- company_name: BIODESIX INC
- filed_at: 2025-04-17T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1439725/000119312525084319/0001193125-25-084319-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1439725/000119312525084319/d861784d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-084319
- JSON: https://secwatch.observer/filing/0001193125-25-084319.json
- Plain text: https://secwatch.observer/filing/0001193125-25-084319.txt

## Key facts
- Executive change
  Charles Watts, M.D. resigned as Director at BIODESIX INC.
  - Action: resigned
  - Role: Director
  source text: On April 15, 2025, Charles Watts, M.D., a member of the Board of Directors (the “Board”) of Biodesix, Inc. (the “Company”), notified the Company of his intention to resign from his position as a director of the Board and as a member of the Compensation Committee, effective at the conclusion of the Company’s 2025 Annual Meeting of Stockholders on May 20, 2025.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1439725/000119312525084319/0001193125-25-084319-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.